Clinical trial
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)
NCT03288493 is registered in ClinicalTrials.gov with Poseida Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)
- Lead sponsor
- Poseida Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 20, 2017
- Completion date
- April 27, 2022
- Enrollment
- 105 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.